Eli Lilly & Co. (LLY) Tops Q1 EPS by 10c; Raises guidance

Go back to Eli Lilly & Co. (LLY) Tops Q1 EPS by 10c; Raises guidance

Eli Lilly (LLY) PT Raised to $1,001 at BMO Capital

April 30, 2024 4:50 PM EDT

BMO Capital analyst Evan David Seigerman raised the price target on Eli Lilly (NYSE: LLY) to $1,001.00 (from $900.00) while maintaining a Outperform rating.

The analyst comments "A high-quality earnings miss is one that 1) characterizes unprecedented demand; 2) justifies performance miss with supply constraints; 3) highlights efforts... More

Eli Lilly (LLY) PT Raised to $885 at Cantor Fitzgerald

April 30, 2024 2:01 PM EDT

Cantor Fitzgerald analyst Louise Chen raised the price target on Eli Lilly (NYSE: LLY) to $885.00 (from $815.00) while maintaining a Overweight rating.

The analyst comments "For 1Q24, US Zepbound revenue was $517MM vs. $363MM for FactSet. Zepbound is already annualizing at over... More

Eli Lilly (LLY) stock climbs on gross margin beat, raised 2024 revenue outlook

April 30, 2024 6:59 AM EDT

(Updated - April 30, 2024 10:00 AM EDT)

Eli Lilly & Co. (NYSE: LLY) saw its shares jump over 7% at the open on Tuesday after the pharmaceutical giant reported better-than-expected earnings and gross margin for the fiscal Q1 2024.

Specifically, Eli Lilly posted earnings per share (EPS) of $2.58, beating the analyst expectations of $2.48. However, the company's revenue for the quarter was $8.77 billion, falling short of the consensus estimate of $8.94 billion.

Importantly, the company's gross margin improved significantly, reaching 80.9% compared to 76.6% in the same period last year... More